Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Avastin’s Orphan Status Withdrawn for Pleural Mesothelioma
June 6, 2017
- MEXT to Consider Company Payment Probe for Private Univ. Hospitals: Official
June 5, 2017
- Inject Intensive Resources for Healthy Lifespan Extension: Honebuto Draft
June 5, 2017
- Draft Honebuto Policy OK’ed by CEFP, Says Distinguish “Me Too” Drugs from Pioneering Meds
June 5, 2017
- MHLW Mulling to Add Clinical Trial Data for Generic Labels
June 2, 2017
- 4 Eligibility Criteria Presented for Conditional Early Approval System
June 2, 2017
- 3rd Sakigake Invitation for Drugs Slated for This Autumn: MHLW
June 2, 2017
- Honebuto Policy to Incorporate Timeline for Drug Pricing Overhaul
June 2, 2017
- MHLW Proposes Thresholds for 5-Scale Cost-Effectiveness Ratings: Chuikyo
June 1, 2017
- Chuikyo Members Oppose Reference Pricing System for LLPs
June 1, 2017
- Payer Reps Push Earlier Application of “Z2” Price Cut for LLPs with Low Gx Rates: Chuikyo
June 1, 2017
- MHLW Advisory Panel Gives Nod to Eli Lilly’s JAK Inhibitor Baricitinib
May 31, 2017
- PhRMA Calls for Expedited Discussions on Inclusion of Vaccines in Public Vaccination Programs
May 31, 2017
- MHLW to Take Strict Action on Xarelto Side Effect Case: Minister
May 31, 2017
- MHLW Orders Label Revisions for Pneumovax NP, 3 Other Products
May 31, 2017
- Lyrica OD Tablets, Other New Dosage Forms to Join NHI Price List on May 31
May 30, 2017
- MHLW Orders Bayer Blanket Probe on Side Effect Reporting
May 30, 2017
- Nusinersen, Tenelia-Canaglu Combo Up for MHLW Panel Review on June 9
May 29, 2017
- Off-Year Revision of NHI Prices “Should Be as Restricted as Possible”: LDP Lawmakers
May 29, 2017
- MOF Panel Calls for Abolishing Price Maintenance Premium, Further Belt-Tightening
May 26, 2017
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…